Results 11 to 20 of about 1,790 (75)

Publication Only [PDF]

open access: yesHemasphere
HemaSphere, Volume 9, Issue S1, June 2025.
europepmc   +2 more sources

Small and state‐funded: An empirical study of liquidations in Scotland

open access: yesInternational Insolvency Review, Volume 32, Issue 3, Page 420-446, Winter 2023., 2023
Abstract There is significant scope for empirical research in the field of corporate insolvency law. This paper seeks to make a valuable contribution to this field of research. It features analysis of data regarding all insolvent liquidations in Scotland that had their end point within a period of a year, specifically 1 October 2019‐30 September 2020 ...
Jonathan Hardman, Alisdair MacPherson
wiley   +1 more source

Therapeutic potential role of vitamin C in prevention and control of heart transplant rejection and cardiac allograft vasculopathy. A need for consideration

open access: yesHealth Science Reports, Volume 6, Issue 11, November 2023., 2023
Abstract The burden of cardiovascular diseases is rising rapidly globally. Heart transplant is one of the most last resort medical option for patients with heart failure. Unfortunately, this surgical intervention is associated with several serious complications including heart transplant rejection (HTR) and Cardiac Allograft Vasculopathy (CAV) which ...
Idd J. Kenedy   +2 more
wiley   +1 more source

Efficient Option Pricing under Levy Processes, with CVA and FVA

open access: yesFrontiers in Applied Mathematics and Statistics, 2015
We generalize the Piterbarg (2010) model to include 1) bilateral default risk as in Burgard and Kjaer (2012), and 2) jumps in the dynamics of the underlying asset using general classes of L'evy processes of exponential type.
Jimmy eLaw   +2 more
doaj   +1 more source

CCPs, Central Clearing, CSA, Credit Collateral and Funding Costs Valuation FAQ: Re-hypothecation, CVA, Closeout, Netting, WWR, Gap-Risk, Initial and Variation Margins, Multiple Discount Curves, FVA? [PDF]

open access: yes, 2013
We present a dialogue on Funding Costs and Counterparty Credit Risk modeling, inclusive of collateral, wrong way risk, gap risk and possible Central Clearing implementation through CCPs.
Brigo, Damiano, Pallavicini, Andrea
core   +1 more source

Credit Valuation Adjustment (CVA) Analytics

open access: yes, 2022
Credit Valuation Adjustment (CVA) is the difference in value of an OTC derivatives position due to counterparty credit risk. More informally, think of CVA as the fair value of buying protection against the counterparty’s potential failure to meet contractual obligations.
openaire   +1 more source

Credit Derivative Evaluation and CVA Under the Benchmark Approach [PDF]

open access: yes, 2015
© 2015, Springer Japan. In this paper, we discuss how to model credit risk under the benchmark approach. Firstly we introduce an affine credit risk model.
Baldeaux, J, Platen, E
core   +1 more source

Rational Multi-Curve Models with Counterparty-Risk Valuation Adjustments [PDF]

open access: yes, 2015
We develop a multi-curve term structure setup in which the modelling ingredients are expressed by rational functionals of Markov processes. We calibrate to LIBOR swaptions data and show that a rational two-factor lognormal multi-curve model is sufficient
Crepey, Stephane   +3 more
core   +2 more sources

An Efficient, Distributable, Risk Neutral Framework for CVA Calculation

open access: yes, 2010
The importance of counterparty credit risk to the derivative contracts was demonstrated consistently throughout the financial crisis of 2008. Accurate valuation of Credit value adjustment (CVA) is essential to reflect the economic values of these risks ...
Juan, Frank, Lu, Dongsheng
core   +1 more source

CVA and FVA to Derivatives Trades Collateralized by Cash

open access: yes, 2013
In this article, we combine replication pricing with expectation pricing for derivative trades that are partially collateralized by cash. The derivatives are replicated by underlying assets and cash, using repurchasing agreement (repo) and margining ...
Wu, Lixin
core   +1 more source

Home - About - Disclaimer - Privacy